The global Vaccine Microarray Patches (VMAPs) market was valued at US$ 22.15 million in 2025 and is anticipated to reach US$ 37.48 million by 2032, at a CAGR of 7.8% from 2026 to 2032.

Vaccine Microarray Patches (VMAPs) Market

The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Vaccine Microarray Patches (VMAPs) competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.

Vaccine microarray patches (VMAPs) are skin-applied patches covered with a dense array of microscopic projections (microneedles) that deliver vaccine antigens into the outer layers of the skin, where immune cells are abundant, to trigger protective immunity with minimal pain. The vaccine can be coated onto solid microprojections or incorporated into dissolvable tips that separate or dissolve after application, leaving no sharps waste. VMAPs are being developed to simplify vaccination by enabling quick administration (potentially even by minimally trained workers or self-use), improving safety by avoiding conventional needles, and, depending on formulation, improving thermostability and reducing cold-chain dependence—features that could be especially valuable for mass immunization and hard-to-reach settings. Vaccine microarray patches cost between $0.85 and $5.00 per dose/patch.

Vaccine Microarray Patches (VMAPs) are manufactured through a combination of vaccine drug-product and microfabricated device supply chains. Upstream, the process starts with vaccine antigen production (cell culture/fermentation or recombinant expression), followed by purification and formulation with stabilizing excipients (e.g., sugars, polymers, buffers, surfactants, sometimes adjuvants) designed to preserve potency during drying and storage; in parallel, suppliers provide microneedle array materials (dissolving polymers/sugars or solid substrates), precision tooling (micro-molds/etching), medical-grade backings/adhesives/liners, and moisture-barrier packaging components. Midstream manufacturing typically includes forming the microarray (molding/etching), loading antigen into tips or coating the projections, controlled drying/curing under tight humidity control, patch assembly/lamination (and sometimes an applicator), then stringent QC/QA for dose uniformity, mechanical insertion performance, sterility/bioburden strategy, and stability. Downstream, VMAPs move through a “combination product” distribution model—often emphasizing humidity-protected primary packs and validated shipping—into immunization channels such as national programs, clinics, pharmacies, or outreach campaigns, where the patch is applied for a specified dwell time and then disposed of (with reduced sharps handling for dissolving designs), with training, traceability, and pharmacovigilance integrated similarly to conventional vaccines.

The North American market for Vaccine Microarray Patches (VMAPs) is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.

The Asia-Pacific market for Vaccine Microarray Patches (VMAPs) is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.

Major global manufacturers of Vaccine Microarray Patches (VMAPs) include Kindeva, Raphas, CosMED Pharmaceutical, Vaxess Technologies, Micron Biomedical, LTS Lohmann Therapie-Systeme, ArrayPatch, CeraVx, Zhongke Microneedle (Beijing) Technology, Zhuhai Youwe Biotechnology, etc. In 2025, the world's top three vendors accounted for approximately % of revenue.

This report delivers a comprehensive overview of the global Vaccine Microarray Patches (VMAPs) market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Vaccine Microarray Patches (VMAPs). The Vaccine Microarray Patches (VMAPs) market size, estimates, and forecasts are provided in terms of sales volume (K Pcs) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.

The report segments the global Vaccine Microarray Patches (VMAPs) market comprehensively. Regional market sizes by Type, by Application, by Microneedle Material, and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.

This report will assist Vaccine Microarray Patches (VMAPs) manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Market Segmentation

Scope of Vaccine Microarray Patches (VMAPs) Market Report

Report Metric	Details
Report Name	Vaccine Microarray Patches (VMAPs) Market
Accounted market size in 2025	US$ 22.15 million
Forecasted market size in 2032	US$ 37.48 million
CAGR	7.8%
Base Year	2025
Forecasted years	2026 - 2032
Segment by Type	Dissolving Non-dissolving
Segment by Microneedle Material	Hyaluronic Acid Taurine Triple-helical Collagen
Segment by Form of Use	Patches Direct Topical
by Application	Routine Childhood Immunization Adolescent / Pre-adolescent Prevention Travel / Endemic Exposure / Post-exposure Respiratory Vaccines with Recurring Demand Outbreak / Pandemic Preparedness
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Kindeva, Raphas, CosMED Pharmaceutical, Vaxess Technologies, Micron Biomedical, LTS Lohmann Therapie-Systeme, ArrayPatch, CeraVx, Zhongke Microneedle (Beijing) Technology, Zhuhai Youwe Biotechnology, Youwei (Zhuhai) Biotechnology, WCC Biomedical, Hisamitsu Pharmaceutical
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, by Microneedle Material, etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for Vaccine Microarray Patches (VMAPs) manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines Vaccine Microarray Patches (VMAPs) sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.

FAQ for this report

How fast is Vaccine Microarray Patches (VMAPs) Market growing?

Ans: The Vaccine Microarray Patches (VMAPs) Market witnessing a CAGR of 7.8% during the forecast period 2026-2032.

What is the Vaccine Microarray Patches (VMAPs) Market size in 2032?

Ans: The Vaccine Microarray Patches (VMAPs) Market size in 2032 will be US$ 37.48 million.

Who are the main players in the Vaccine Microarray Patches (VMAPs) Market report?

Ans: The main players in the Vaccine Microarray Patches (VMAPs) Market are Kindeva, Raphas, CosMED Pharmaceutical, Vaxess Technologies, Micron Biomedical, LTS Lohmann Therapie-Systeme, ArrayPatch, CeraVx, Zhongke Microneedle (Beijing) Technology, Zhuhai Youwe Biotechnology, Youwei (Zhuhai) Biotechnology, WCC Biomedical, Hisamitsu Pharmaceutical

What are the Application segmentation covered in the Vaccine Microarray Patches (VMAPs) Market report?

Ans: The Applications covered in the Vaccine Microarray Patches (VMAPs) Market report are Routine Childhood Immunization, Adolescent / Pre-adolescent Prevention, Travel / Endemic Exposure / Post-exposure, Respiratory Vaccines with Recurring Demand, Outbreak / Pandemic Preparedness

What are the Type segmentation covered in the Vaccine Microarray Patches (VMAPs) Market report?

Ans: The Types covered in the Vaccine Microarray Patches (VMAPs) Market report are Dissolving, Non-dissolving

1 Vaccine Microarray Patches (VMAPs) Market Overview

1.1 Product Definition

1.2 Vaccine Microarray Patches (VMAPs) by Type

1.2.1 Global Vaccine Microarray Patches (VMAPs) Market Value by Type: 2025 vs 2032

1.2.2 Dissolving

1.2.3 Non-dissolving

1.3 Vaccine Microarray Patches (VMAPs) by Microneedle Material

1.3.1 Global Vaccine Microarray Patches (VMAPs) Market Value by Microneedle Material: 2025 vs 2032

1.3.2 Hyaluronic Acid

1.3.3 Taurine

1.3.4 Triple-helical Collagen

1.4 Vaccine Microarray Patches (VMAPs) by Form of Use

1.4.1 Global Vaccine Microarray Patches (VMAPs) Market Value by Form of Use: 2025 vs 2032

1.4.2 Patches

1.4.3 Direct Topical

1.5 Vaccine Microarray Patches (VMAPs) by Application

1.5.1 Global Vaccine Microarray Patches (VMAPs) Market Value by Application: 2025 vs 2032

1.5.2 Routine Childhood Immunization

1.5.3 Adolescent / Pre-adolescent Prevention

1.5.4 Travel / Endemic Exposure / Post-exposure

1.5.5 Respiratory Vaccines with Recurring Demand

1.5.6 Outbreak / Pandemic Preparedness

1.6 Global Vaccine Microarray Patches (VMAPs) Market Size Estimates and Forecasts

1.6.1 Global Vaccine Microarray Patches (VMAPs) Revenue 2021–2032

1.6.2 Global Vaccine Microarray Patches (VMAPs) Sales 2021–2032

1.6.3 Global Vaccine Microarray Patches (VMAPs) Market Average Price (2021–2032)

1.7 Assumptions and Limitations

2 Vaccine Microarray Patches (VMAPs) Market Competition by Manufacturers

2.1 Global Vaccine Microarray Patches (VMAPs) Sales Market Share by Manufacturers (2021–2026)

2.2 Global Vaccine Microarray Patches (VMAPs) Revenue Market Share by Manufacturers (2021–2026)

2.3 Global Vaccine Microarray Patches (VMAPs) Average Price by Manufacturers (2021–2026)

2.4 Global Key Players of Vaccine Microarray Patches (VMAPs), Industry Ranking, 2023 vs 2024 vs 2025

2.5 Global Key Manufacturers of Vaccine Microarray Patches (VMAPs), Manufacturing Sites and Headquarters

2.6 Global Key Manufacturers of Vaccine Microarray Patches (VMAPs), Product Types and Applications

2.7 Global Key Manufacturers of Vaccine Microarray Patches (VMAPs), Date of Entry into the Industry

2.8 Global Vaccine Microarray Patches (VMAPs) Market Competitive Situation and Trends

2.8.1 Global Vaccine Microarray Patches (VMAPs) Market Concentration Rate

2.8.2 The Top 5 and Top 10 Global Vaccine Microarray Patches (VMAPs) Players Market Share by Revenue

2.8.3 Global Vaccine Microarray Patches (VMAPs) Market Share by Company Tier (Tier 1, Tier 2, Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global Vaccine Microarray Patches (VMAPs) Market Scenario by Region

3.1 Global Vaccine Microarray Patches (VMAPs) Market Size by Region: 2021 vs 2025 vs 2032

3.2 Global Vaccine Microarray Patches (VMAPs) Sales by Region: 2021–2032

3.2.1 Global Vaccine Microarray Patches (VMAPs) Sales by Region: 2021–2026

3.2.2 Global Vaccine Microarray Patches (VMAPs) Sales by Region: 2027–2032

3.3 Global Vaccine Microarray Patches (VMAPs) Revenue by Region: 2021–2032

3.3.1 Global Vaccine Microarray Patches (VMAPs) Revenue by Region: 2021–2026

3.3.2 Global Vaccine Microarray Patches (VMAPs) Revenue by Region: 2027–2032

3.4 North America Vaccine Microarray Patches (VMAPs) Market Facts & Figures by Country

3.4.1 North America Vaccine Microarray Patches (VMAPs) Market Size by Country: 2021 vs 2025 vs 2032

3.4.2 North America Vaccine Microarray Patches (VMAPs) Sales by Country (2021–2032)

3.4.3 North America Vaccine Microarray Patches (VMAPs) Revenue by Country (2021–2032)

3.4.4 United States

3.4.5 Canada

3.5 Europe Vaccine Microarray Patches (VMAPs) Market Facts & Figures by Country

3.5.1 Europe Vaccine Microarray Patches (VMAPs) Market Size by Country: 2021 vs 2025 vs 2032

3.5.2 Europe Vaccine Microarray Patches (VMAPs) Sales by Country (2021–2032)

3.5.3 Europe Vaccine Microarray Patches (VMAPs) Revenue by Country (2021–2032)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Vaccine Microarray Patches (VMAPs) Market Facts & Figures by Region

3.6.1 Asia Pacific Vaccine Microarray Patches (VMAPs) Market Size by Region: 2021 vs 2025 vs 2032

3.6.2 Asia Pacific Vaccine Microarray Patches (VMAPs) Sales by Region (2021–2032)

3.6.3 Asia Pacific Vaccine Microarray Patches (VMAPs) Revenue by Region (2021–2032)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Southeast Asia

3.7 Latin America Vaccine Microarray Patches (VMAPs) Market Facts & Figures by Country

3.7.1 Latin America Vaccine Microarray Patches (VMAPs) Market Size by Country: 2021 vs 2025 vs 2032

3.7.2 Latin America Vaccine Microarray Patches (VMAPs) Sales by Country (2021–2032)

3.7.3 Latin America Vaccine Microarray Patches (VMAPs) Revenue by Country (2021–2032)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.7.7 Colombia

3.8 Middle East and Africa Vaccine Microarray Patches (VMAPs) Market Facts & Figures by Country

3.8.1 Middle East and Africa Vaccine Microarray Patches (VMAPs) Market Size by Country: 2021 vs 2025 vs 2032

3.8.2 Middle East and Africa Vaccine Microarray Patches (VMAPs) Sales by Country (2021–2032)

3.8.3 Middle East and Africa Vaccine Microarray Patches (VMAPs) Revenue by Country (2021–2032)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global Vaccine Microarray Patches (VMAPs) Sales by Type (2021–2032)

4.1.1 Global Vaccine Microarray Patches (VMAPs) Sales by Type (2021–2026)

4.1.2 Global Vaccine Microarray Patches (VMAPs) Sales by Type (2027–2032)

4.1.3 Global Vaccine Microarray Patches (VMAPs) Sales Market Share by Type (2021–2032)

4.2 Global Vaccine Microarray Patches (VMAPs) Revenue by Type (2021–2032)

4.2.1 Global Vaccine Microarray Patches (VMAPs) Revenue by Type (2021–2026)

4.2.2 Global Vaccine Microarray Patches (VMAPs) Revenue by Type (2027–2032)

4.2.3 Global Vaccine Microarray Patches (VMAPs) Revenue Market Share by Type (2021–2032)

4.3 Global Vaccine Microarray Patches (VMAPs) Price by Type (2021–2032)

5 Segment by Application

5.1 Global Vaccine Microarray Patches (VMAPs) Sales by Application (2021–2032)

5.1.1 Global Vaccine Microarray Patches (VMAPs) Sales by Application (2021–2026)

5.1.2 Global Vaccine Microarray Patches (VMAPs) Sales by Application (2027–2032)

5.1.3 Global Vaccine Microarray Patches (VMAPs) Sales Market Share by Application (2021–2032)

5.2 Global Vaccine Microarray Patches (VMAPs) Revenue by Application (2021–2032)

5.2.1 Global Vaccine Microarray Patches (VMAPs) Revenue by Application (2021–2026)

5.2.2 Global Vaccine Microarray Patches (VMAPs) Revenue by Application (2027–2032)

5.2.3 Global Vaccine Microarray Patches (VMAPs) Revenue Market Share by Application (2021–2032)

5.3 Global Vaccine Microarray Patches (VMAPs) Price by Application (2021–2032)

6 Key Companies Profiled

6.1 Kindeva

6.1.1 Kindeva Company Information

6.1.2 Kindeva Description and Business Overview

6.1.3 Kindeva Vaccine Microarray Patches (VMAPs) Sales, Revenue, and Gross Margin (2021–2026)

6.1.4 Kindeva Vaccine Microarray Patches (VMAPs) Product Portfolio

6.1.5 Kindeva Recent Developments/Updates

6.2 Raphas

6.2.1 Raphas Company Information

6.2.2 Raphas Description and Business Overview

6.2.3 Raphas Vaccine Microarray Patches (VMAPs) Sales, Revenue, and Gross Margin (2021–2026)

6.2.4 Raphas Vaccine Microarray Patches (VMAPs) Product Portfolio

6.2.5 Raphas Recent Developments/Updates

6.3 CosMED Pharmaceutical

6.3.1 CosMED Pharmaceutical Company Information

6.3.2 CosMED Pharmaceutical Description and Business Overview

6.3.3 CosMED Pharmaceutical Vaccine Microarray Patches (VMAPs) Sales, Revenue, and Gross Margin (2021–2026)

6.3.4 CosMED Pharmaceutical Vaccine Microarray Patches (VMAPs) Product Portfolio

6.3.5 CosMED Pharmaceutical Recent Developments/Updates

6.4 Vaxess Technologies

6.4.1 Vaxess Technologies Company Information

6.4.2 Vaxess Technologies Description and Business Overview

6.4.3 Vaxess Technologies Vaccine Microarray Patches (VMAPs) Sales, Revenue, and Gross Margin (2021–2026)

6.4.4 Vaxess Technologies Vaccine Microarray Patches (VMAPs) Product Portfolio

6.4.5 Vaxess Technologies Recent Developments/Updates

6.5 Micron Biomedical

6.5.1 Micron Biomedical Company Information

6.5.2 Micron Biomedical Description and Business Overview

6.5.3 Micron Biomedical Vaccine Microarray Patches (VMAPs) Sales, Revenue, and Gross Margin (2021–2026)

6.5.4 Micron Biomedical Vaccine Microarray Patches (VMAPs) Product Portfolio

6.5.5 Micron Biomedical Recent Developments/Updates

6.6 LTS Lohmann Therapie-Systeme

6.6.1 LTS Lohmann Therapie-Systeme Company Information

6.6.2 LTS Lohmann Therapie-Systeme Description and Business Overview

6.6.3 LTS Lohmann Therapie-Systeme Vaccine Microarray Patches (VMAPs) Sales, Revenue, and Gross Margin (2021–2026)

6.6.4 LTS Lohmann Therapie-Systeme Vaccine Microarray Patches (VMAPs) Product Portfolio

6.6.5 LTS Lohmann Therapie-Systeme Recent Developments/Updates

6.7 ArrayPatch

6.7.1 ArrayPatch Company Information

6.7.2 ArrayPatch Description and Business Overview

6.7.3 ArrayPatch Vaccine Microarray Patches (VMAPs) Sales, Revenue, and Gross Margin (2021–2026)

6.7.4 ArrayPatch Vaccine Microarray Patches (VMAPs) Product Portfolio

6.7.5 ArrayPatch Recent Developments/Updates

6.8 CeraVx

6.8.1 CeraVx Company Information

6.8.2 CeraVx Description and Business Overview

6.8.3 CeraVx Vaccine Microarray Patches (VMAPs) Sales, Revenue, and Gross Margin (2021–2026)

6.8.4 CeraVx Vaccine Microarray Patches (VMAPs) Product Portfolio

6.8.5 CeraVx Recent Developments/Updates

6.9 Zhongke Microneedle (Beijing) Technology

6.9.1 Zhongke Microneedle (Beijing) Technology Company Information

6.9.2 Zhongke Microneedle (Beijing) Technology Description and Business Overview

6.9.3 Zhongke Microneedle (Beijing) Technology Vaccine Microarray Patches (VMAPs) Sales, Revenue, and Gross Margin (2021–2026)

6.9.4 Zhongke Microneedle (Beijing) Technology Vaccine Microarray Patches (VMAPs) Product Portfolio

6.9.5 Zhongke Microneedle (Beijing) Technology Recent Developments/Updates

6.10 Zhuhai Youwe Biotechnology

6.10.1 Zhuhai Youwe Biotechnology Company Information

6.10.2 Zhuhai Youwe Biotechnology Description and Business Overview

6.10.3 Zhuhai Youwe Biotechnology Vaccine Microarray Patches (VMAPs) Sales, Revenue, and Gross Margin (2021–2026)

6.10.4 Zhuhai Youwe Biotechnology Vaccine Microarray Patches (VMAPs) Product Portfolio

6.10.5 Zhuhai Youwe Biotechnology Recent Developments/Updates

6.11 Youwei (Zhuhai) Biotechnology

6.11.1 Youwei (Zhuhai) Biotechnology Company Information

6.11.2 Youwei (Zhuhai) Biotechnology Description and Business Overview

6.11.3 Youwei (Zhuhai) Biotechnology Vaccine Microarray Patches (VMAPs) Sales, Revenue, and Gross Margin (2021–2026)

6.11.4 Youwei (Zhuhai) Biotechnology Vaccine Microarray Patches (VMAPs) Product Portfolio

6.11.5 Youwei (Zhuhai) Biotechnology Recent Developments/Updates

6.12 WCC Biomedical

6.12.1 WCC Biomedical Company Information

6.12.2 WCC Biomedical Description and Business Overview

6.12.3 WCC Biomedical Vaccine Microarray Patches (VMAPs) Sales, Revenue, and Gross Margin (2021–2026)

6.12.4 WCC Biomedical Vaccine Microarray Patches (VMAPs) Product Portfolio

6.12.5 WCC Biomedical Recent Developments/Updates

6.13 Hisamitsu Pharmaceutical

6.13.1 Hisamitsu Pharmaceutical Company Information

6.13.2 Hisamitsu Pharmaceutical Description and Business Overview

6.13.3 Hisamitsu Pharmaceutical Vaccine Microarray Patches (VMAPs) Sales, Revenue, and Gross Margin (2021–2026)

6.13.4 Hisamitsu Pharmaceutical Vaccine Microarray Patches (VMAPs) Product Portfolio

6.13.5 Hisamitsu Pharmaceutical Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Vaccine Microarray Patches (VMAPs) Industry Chain Analysis

7.2 Vaccine Microarray Patches (VMAPs) Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Vaccine Microarray Patches (VMAPs) Production Mode & Process Analysis

7.4 Vaccine Microarray Patches (VMAPs) Sales and Marketing

7.4.1 Vaccine Microarray Patches (VMAPs) Sales Channels

7.4.2 Vaccine Microarray Patches (VMAPs) Distributors

7.5 Vaccine Microarray Patches (VMAPs) Customer Analysis

8 Vaccine Microarray Patches (VMAPs) Market Dynamics

8.1 Vaccine Microarray Patches (VMAPs) Industry Trends

8.2 Vaccine Microarray Patches (VMAPs) Market Drivers

8.3 Vaccine Microarray Patches (VMAPs) Market Challenges

8.4 Vaccine Microarray Patches (VMAPs) Market Restraints

8.5 Impact of U.S. Tariffs

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

KINDEVA

Raphas

Cosmed Pharmaceutical

Vaxess Technologies

Micron Biomedical

LTS Lohmann Therapie-Systeme

ArrayPatch

CeraVx

Zhongke Microneedle (Beijing) Technology

Zhuhai Youwe Biotechnology

Youwei (Zhuhai) Biotechnology

WCC Biomedical

Hisamitsu Pharmaceutical

List of Tables

Table 1. Global Vaccine Microarray Patches (VMAPs) Market Value by Type (US$ Million), 2025 vs 2032

Table 2. Global Vaccine Microarray Patches (VMAPs) Market Value by Microneedle Material (US$ Million), 2025 vs 2032

Table 3. Global Vaccine Microarray Patches (VMAPs) Market Value by Form of Use (US$ Million), 2025 vs 2032

Table 4. Global Vaccine Microarray Patches (VMAPs) Market Value by Application (US$ Million), 2025 vs 2032

Table 5. Global Vaccine Microarray Patches (VMAPs) Market Competitive Situation by Manufacturers in 2025

Table 6. Global Vaccine Microarray Patches (VMAPs) Sales (K Pcs) of Key Manufacturers (2021–2026)

Table 7. Global Vaccine Microarray Patches (VMAPs) Sales Market Share by Manufacturers (2021–2026)

Table 8. Global Vaccine Microarray Patches (VMAPs) Revenue (US$ Million) by Manufacturers (2021–2026)

Table 9. Global Vaccine Microarray Patches (VMAPs) Revenue Share by Manufacturers (2021–2026)

Table 10. Global Market Vaccine Microarray Patches (VMAPs) Average Price (US$/Pc) of Key Manufacturers (2021–2026)

Table 11. Global Key Players of Vaccine Microarray Patches (VMAPs), Industry Ranking, 2023 vs 2024 vs 2025

Table 12. Global Key Manufacturers of Vaccine Microarray Patches (VMAPs), Manufacturing Sites and Headquarters

Table 13. Global Key Manufacturers of Vaccine Microarray Patches (VMAPs), Product Types and Applications

Table 14. Global Key Manufacturers of Vaccine Microarray Patches (VMAPs), Date of Entry into the Industry

Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 16. Global Vaccine Microarray Patches (VMAPs) Companies by Tier (Tier 1, Tier 2, Tier 3), based on Vaccine Microarray Patches (VMAPs) Revenue, 2025

Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 18. Global Vaccine Microarray Patches (VMAPs) Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

Table 19. Global Vaccine Microarray Patches (VMAPs) Sales by Region (K Pcs), 2021–2026

Table 20. Global Vaccine Microarray Patches (VMAPs) Sales Market Share by Region (2021–2026)

Table 21. Global Vaccine Microarray Patches (VMAPs) Sales by Region (K Pcs), 2027–2032

Table 22. Global Vaccine Microarray Patches (VMAPs) Sales Market Share by Region (2027–2032)

Table 23. Global Vaccine Microarray Patches (VMAPs) Revenue by Region (US$ Million), 2021–2026

Table 24. Global Vaccine Microarray Patches (VMAPs) Revenue Market Share by Region (2021–2026)

Table 25. Global Vaccine Microarray Patches (VMAPs) Revenue by Region (US$ Million), 2027–2032

Table 26. Global Vaccine Microarray Patches (VMAPs) Revenue Market Share by Region (2027–2032)

Table 27. North America Vaccine Microarray Patches (VMAPs) Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

Table 28. North America Vaccine Microarray Patches (VMAPs) Sales by Country (K Pcs), 2021–2026

Table 29. North America Vaccine Microarray Patches (VMAPs) Sales by Country (K Pcs), 2027–2032

Table 30. North America Vaccine Microarray Patches (VMAPs) Revenue by Country (US$ Million), 2021–2026

Table 31. North America Vaccine Microarray Patches (VMAPs) Revenue by Country (US$ Million), 2027–2032

Table 32. Europe Vaccine Microarray Patches (VMAPs) Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

Table 33. Europe Vaccine Microarray Patches (VMAPs) Sales by Country (K Pcs), 2021–2026

Table 34. Europe Vaccine Microarray Patches (VMAPs) Sales by Country (K Pcs), 2027–2032

Table 35. Europe Vaccine Microarray Patches (VMAPs) Revenue by Country (US$ Million), 2021–2026

Table 36. Europe Vaccine Microarray Patches (VMAPs) Revenue by Country (US$ Million), 2027–2032

Table 37. Asia Pacific Vaccine Microarray Patches (VMAPs) Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)

Table 38. Asia Pacific Vaccine Microarray Patches (VMAPs) Sales by Region (K Pcs), 2021–2026

Table 39. Asia Pacific Vaccine Microarray Patches (VMAPs) Sales by Region (K Pcs), 2027–2032

Table 40. Asia Pacific Vaccine Microarray Patches (VMAPs) Revenue by Region (US$ Million), 2021–2026

Table 41. Asia Pacific Vaccine Microarray Patches (VMAPs) Revenue by Region (US$ Million), 2027–2032

Table 42. Latin America Vaccine Microarray Patches (VMAPs) Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

Table 43. Latin America Vaccine Microarray Patches (VMAPs) Sales by Country (K Pcs), 2021–2026

Table 44. Latin America Vaccine Microarray Patches (VMAPs) Sales by Country (K Pcs), 2027–2032

Table 45. Latin America Vaccine Microarray Patches (VMAPs) Revenue by Country (US$ Million), 2021–2026

Table 46. Latin America Vaccine Microarray Patches (VMAPs) Revenue by Country (US$ Million), 2027–2032

Table 47. Middle East and Africa Vaccine Microarray Patches (VMAPs) Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

Table 48. Middle East and Africa Vaccine Microarray Patches (VMAPs) Sales by Country (K Pcs), 2021–2026

Table 49. Middle East and Africa Vaccine Microarray Patches (VMAPs) Sales by Country (K Pcs), 2027–2032

Table 50. Middle East and Africa Vaccine Microarray Patches (VMAPs) Revenue by Country (US$ Million), 2021–2026

Table 51. Middle East and Africa Vaccine Microarray Patches (VMAPs) Revenue by Country (US$ Million), 2027–2032

Table 52. Global Vaccine Microarray Patches (VMAPs) Sales (K Pcs) by Type (2021–2026)

Table 53. Global Vaccine Microarray Patches (VMAPs) Sales (K Pcs) by Type (2027–2032)

Table 54. Global Vaccine Microarray Patches (VMAPs) Sales Market Share by Type (2021–2026)

Table 55. Global Vaccine Microarray Patches (VMAPs) Sales Market Share by Type (2027–2032)

Table 56. Global Vaccine Microarray Patches (VMAPs) Revenue (US$ Million) by Type (2021–2026)

Table 57. Global Vaccine Microarray Patches (VMAPs) Revenue (US$ Million) by Type (2027–2032)

Table 58. Global Vaccine Microarray Patches (VMAPs) Revenue Market Share by Type (2021–2026)

Table 59. Global Vaccine Microarray Patches (VMAPs) Revenue Market Share by Type (2027–2032)

Table 60. Global Vaccine Microarray Patches (VMAPs) Price (US$/Pc) by Type (2021–2026)

Table 61. Global Vaccine Microarray Patches (VMAPs) Price (US$/Pc) by Type (2027–2032)

Table 62. Global Vaccine Microarray Patches (VMAPs) Sales (K Pcs) by Application (2021–2026)

Table 63. Global Vaccine Microarray Patches (VMAPs) Sales (K Pcs) by Application (2027–2032)

Table 64. Global Vaccine Microarray Patches (VMAPs) Sales Market Share by Application (2021–2026)

Table 65. Global Vaccine Microarray Patches (VMAPs) Sales Market Share by Application (2027–2032)

Table 66. Global Vaccine Microarray Patches (VMAPs) Revenue (US$ Million) by Application (2021–2026)

Table 67. Global Vaccine Microarray Patches (VMAPs) Revenue (US$ Million) by Application (2027–2032)

Table 68. Global Vaccine Microarray Patches (VMAPs) Revenue Market Share by Application (2021–2026)

Table 69. Global Vaccine Microarray Patches (VMAPs) Revenue Market Share by Application (2027–2032)

Table 70. Global Vaccine Microarray Patches (VMAPs) Price (US$/Pc) by Application (2021–2026)

Table 71. Global Vaccine Microarray Patches (VMAPs) Price (US$/Pc) by Application (2027–2032)

Table 72. Kindeva Company Information

Table 73. Kindeva Description and Business Overview

Table 74. Kindeva Vaccine Microarray Patches (VMAPs) Sales (K Pcs), Revenue (US$ Million), Price (US$/Pc), and Gross Margin (2021–2026)

Table 75. Kindeva Vaccine Microarray Patches (VMAPs) Product

Table 76. Kindeva Recent Developments/Updates

Table 77. Raphas Company Information

Table 78. Raphas Description and Business Overview

Table 79. Raphas Vaccine Microarray Patches (VMAPs) Sales (K Pcs), Revenue (US$ Million), Price (US$/Pc), and Gross Margin (2021–2026)

Table 80. Raphas Vaccine Microarray Patches (VMAPs) Product

Table 81. Raphas Recent Developments/Updates

Table 82. CosMED Pharmaceutical Company Information

Table 83. CosMED Pharmaceutical Description and Business Overview

Table 84. CosMED Pharmaceutical Vaccine Microarray Patches (VMAPs) Sales (K Pcs), Revenue (US$ Million), Price (US$/Pc), and Gross Margin (2021–2026)

Table 85. CosMED Pharmaceutical Vaccine Microarray Patches (VMAPs) Product

Table 86. CosMED Pharmaceutical Recent Developments/Updates

Table 87. Vaxess Technologies Company Information

Table 88. Vaxess Technologies Description and Business Overview

Table 89. Vaxess Technologies Vaccine Microarray Patches (VMAPs) Sales (K Pcs), Revenue (US$ Million), Price (US$/Pc), and Gross Margin (2021–2026)

Table 90. Vaxess Technologies Vaccine Microarray Patches (VMAPs) Product

Table 91. Vaxess Technologies Recent Developments/Updates

Table 92. Micron Biomedical Company Information

Table 93. Micron Biomedical Description and Business Overview

Table 94. Micron Biomedical Vaccine Microarray Patches (VMAPs) Sales (K Pcs), Revenue (US$ Million), Price (US$/Pc), and Gross Margin (2021–2026)

Table 95. Micron Biomedical Vaccine Microarray Patches (VMAPs) Product

Table 96. Micron Biomedical Recent Developments/Updates

Table 97. LTS Lohmann Therapie-Systeme Company Information

Table 98. LTS Lohmann Therapie-Systeme Description and Business Overview

Table 99. LTS Lohmann Therapie-Systeme Vaccine Microarray Patches (VMAPs) Sales (K Pcs), Revenue (US$ Million), Price (US$/Pc), and Gross Margin (2021–2026)

Table 100. LTS Lohmann Therapie-Systeme Vaccine Microarray Patches (VMAPs) Product

Table 101. LTS Lohmann Therapie-Systeme Recent Developments/Updates

Table 102. ArrayPatch Company Information

Table 103. ArrayPatch Description and Business Overview

Table 104. ArrayPatch Vaccine Microarray Patches (VMAPs) Sales (K Pcs), Revenue (US$ Million), Price (US$/Pc), and Gross Margin (2021–2026)

Table 105. ArrayPatch Vaccine Microarray Patches (VMAPs) Product

Table 106. ArrayPatch Recent Developments/Updates

Table 107. CeraVx Company Information

Table 108. CeraVx Description and Business Overview

Table 109. CeraVx Vaccine Microarray Patches (VMAPs) Sales (K Pcs), Revenue (US$ Million), Price (US$/Pc), and Gross Margin (2021–2026)

Table 110. CeraVx Vaccine Microarray Patches (VMAPs) Product

Table 111. CeraVx Recent Developments/Updates

Table 112. Zhongke Microneedle (Beijing) Technology Company Information

Table 113. Zhongke Microneedle (Beijing) Technology Description and Business Overview

Table 114. Zhongke Microneedle (Beijing) Technology Vaccine Microarray Patches (VMAPs) Sales (K Pcs), Revenue (US$ Million), Price (US$/Pc), and Gross Margin (2021–2026)

Table 115. Zhongke Microneedle (Beijing) Technology Vaccine Microarray Patches (VMAPs) Product

Table 116. Zhongke Microneedle (Beijing) Technology Recent Developments/Updates

Table 117. Zhuhai Youwe Biotechnology Company Information

Table 118. Zhuhai Youwe Biotechnology Description and Business Overview

Table 119. Zhuhai Youwe Biotechnology Vaccine Microarray Patches (VMAPs) Sales (K Pcs), Revenue (US$ Million), Price (US$/Pc), and Gross Margin (2021–2026)

Table 120. Zhuhai Youwe Biotechnology Vaccine Microarray Patches (VMAPs) Product

Table 121. Zhuhai Youwe Biotechnology Recent Developments/Updates

Table 122. Youwei (Zhuhai) Biotechnology Company Information

Table 123. Youwei (Zhuhai) Biotechnology Description and Business Overview

Table 124. Youwei (Zhuhai) Biotechnology Vaccine Microarray Patches (VMAPs) Sales (K Pcs), Revenue (US$ Million), Price (US$/Pc), and Gross Margin (2021–2026)

Table 125. Youwei (Zhuhai) Biotechnology Vaccine Microarray Patches (VMAPs) Product

Table 126. Youwei (Zhuhai) Biotechnology Recent Developments/Updates

Table 127. WCC Biomedical Company Information

Table 128. WCC Biomedical Description and Business Overview

Table 129. WCC Biomedical Vaccine Microarray Patches (VMAPs) Sales (K Pcs), Revenue (US$ Million), Price (US$/Pc), and Gross Margin (2021–2026)

Table 130. WCC Biomedical Vaccine Microarray Patches (VMAPs) Product

Table 131. WCC Biomedical Recent Developments/Updates

Table 132. Hisamitsu Pharmaceutical Company Information

Table 133. Hisamitsu Pharmaceutical Description and Business Overview

Table 134. Hisamitsu Pharmaceutical Vaccine Microarray Patches (VMAPs) Sales (K Pcs), Revenue (US$ Million), Price (US$/Pc), and Gross Margin (2021–2026)

Table 135. Hisamitsu Pharmaceutical Vaccine Microarray Patches (VMAPs) Product

Table 136. Hisamitsu Pharmaceutical Recent Developments/Updates

Table 137. Key Raw Materials Lists

Table 138. Raw Materials Key Suppliers Lists

Table 139. Vaccine Microarray Patches (VMAPs) Distributors List

Table 140. Vaccine Microarray Patches (VMAPs) Customers List

Table 141. Vaccine Microarray Patches (VMAPs) Market Trends

Table 142. Vaccine Microarray Patches (VMAPs) Market Drivers

Table 143. Vaccine Microarray Patches (VMAPs) Market Challenges

Table 144. Vaccine Microarray Patches (VMAPs) Market Restraints

Table 145. Research Programs/Design for This Report

Table 146. Key Data Information from Secondary Sources

Table 147. Key Data Information from Primary Sources

Table 148. Authors List of This Report

List of Figures

Figure 1. Product Picture of Vaccine Microarray Patches (VMAPs)

Figure 2. Global Vaccine Microarray Patches (VMAPs) Market Value by Type (US$ Million), 2021–2032

Figure 3. Global Vaccine Microarray Patches (VMAPs) Market Share by Type: 2025 & 2032

Figure 4. Dissolving Product Picture

Figure 5. Non-dissolving Product Picture

Figure 6. Global Vaccine Microarray Patches (VMAPs) Market Value by Microneedle Material (US$ Million), 2021–2032

Figure 7. Global Vaccine Microarray Patches (VMAPs) Market Share by Microneedle Material: 2025 vs 2032

Figure 8. Hyaluronic Acid Product Picture

Figure 9. Taurine Product Picture

Figure 10. Triple-helical Collagen Product Picture

Figure 11. Global Vaccine Microarray Patches (VMAPs) Market Value by Form of Use (US$ Million), 2021–2032

Figure 12. Global Vaccine Microarray Patches (VMAPs) Market Share by Form of Use: 2025 vs 2032

Figure 13. Patches Product Picture

Figure 14. Direct Topical Product Picture

Figure 15. Global Vaccine Microarray Patches (VMAPs) Market Value by Application (US$ Million), 2021–2032

Figure 16. Global Vaccine Microarray Patches (VMAPs) Market Share by Application: 2025 & 2032

Figure 17. Routine Childhood Immunization

Figure 18. Adolescent / Pre-adolescent Prevention

Figure 19. Travel / Endemic Exposure / Post-exposure

Figure 20. Respiratory Vaccines with Recurring Demand

Figure 21. Outbreak / Pandemic Preparedness

Figure 22. Global Vaccine Microarray Patches (VMAPs) Revenue, (US$ Million), 2021 vs 2025 vs 2032

Figure 23. Global Vaccine Microarray Patches (VMAPs) Market Size (US$ Million), 2021–2032

Figure 24. Global Vaccine Microarray Patches (VMAPs) Sales (K Pcs), 2021–2032

Figure 25. Global Vaccine Microarray Patches (VMAPs) Average Price (US$/Pc), 2021–2032

Figure 26. Vaccine Microarray Patches (VMAPs) Report Years Considered

Figure 27. Vaccine Microarray Patches (VMAPs) Sales Share by Manufacturers in 2025

Figure 28. Global Vaccine Microarray Patches (VMAPs) Revenue Share by Manufacturers in 2025

Figure 29. Top 5 and Top 10 Global Vaccine Microarray Patches (VMAPs) Players: Market Share by Revenue in Vaccine Microarray Patches (VMAPs) in 2025

Figure 30. Vaccine Microarray Patches (VMAPs) Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025

Figure 31. Global Vaccine Microarray Patches (VMAPs) Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

Figure 32. North America Vaccine Microarray Patches (VMAPs) Sales Market Share by Country (2021–2032)

Figure 33. North America Vaccine Microarray Patches (VMAPs) Revenue Market Share by Country (2021–2032)

Figure 34. United States Vaccine Microarray Patches (VMAPs) Revenue Growth Rate (US$ Million), 2021–2032

Figure 35. Canada Vaccine Microarray Patches (VMAPs) Revenue Growth Rate (US$ Million), 2021–2032

Figure 36. Europe Vaccine Microarray Patches (VMAPs) Sales Market Share by Country (2021–2032)

Figure 37. Europe Vaccine Microarray Patches (VMAPs) Revenue Market Share by Country (2021–2032)

Figure 38. Germany Vaccine Microarray Patches (VMAPs) Revenue Growth Rate (US$ Million), 2021–2032

Figure 39. France Vaccine Microarray Patches (VMAPs) Revenue Growth Rate (US$ Million), 2021–2032

Figure 40. U.K. Vaccine Microarray Patches (VMAPs) Revenue Growth Rate (US$ Million), 2021–2032

Figure 41. Italy Vaccine Microarray Patches (VMAPs) Revenue Growth Rate (US$ Million), 2021–2032

Figure 42. Russia Vaccine Microarray Patches (VMAPs) Revenue Growth Rate (US$ Million), 2021–2032

Figure 43. Asia Pacific Vaccine Microarray Patches (VMAPs) Sales Market Share by Region (2021–2032)

Figure 44. Asia Pacific Vaccine Microarray Patches (VMAPs) Revenue Market Share by Region (2021–2032)

Figure 45. China Vaccine Microarray Patches (VMAPs) Revenue Growth Rate (US$ Million), 2021–2032

Figure 46. Japan Vaccine Microarray Patches (VMAPs) Revenue Growth Rate (US$ Million), 2021–2032

Figure 47. South Korea Vaccine Microarray Patches (VMAPs) Revenue Growth Rate (US$ Million), 2021–2032

Figure 48. India Vaccine Microarray Patches (VMAPs) Revenue Growth Rate (US$ Million), 2021–2032

Figure 49. Australia Vaccine Microarray Patches (VMAPs) Revenue Growth Rate (US$ Million), 2021–2032

Figure 50. China Taiwan Vaccine Microarray Patches (VMAPs) Revenue Growth Rate (US$ Million), 2021–2032

Figure 51. Southeast Asia Vaccine Microarray Patches (VMAPs) Revenue Growth Rate (US$ Million), 2021–2032

Figure 52. Latin America Vaccine Microarray Patches (VMAPs) Sales Market Share by Country (2021–2032)

Figure 53. Latin America Vaccine Microarray Patches (VMAPs) Revenue Market Share by Country (2021–2032)

Figure 54. Mexico Vaccine Microarray Patches (VMAPs) Revenue Growth Rate (US$ Million), 2021–2032

Figure 55. Brazil Vaccine Microarray Patches (VMAPs) Revenue Growth Rate (US$ Million), 2021–2032

Figure 56. Argentina Vaccine Microarray Patches (VMAPs) Revenue Growth Rate (US$ Million), 2021–2032

Figure 57. Colombia Vaccine Microarray Patches (VMAPs) Revenue Growth Rate (US$ Million), 2021–2032

Figure 58. Middle East and Africa Vaccine Microarray Patches (VMAPs) Sales Market Share by Country (2021–2032)

Figure 59. Middle East and Africa Vaccine Microarray Patches (VMAPs) Revenue Market Share by Country (2021–2032)

Figure 60. Turkey Vaccine Microarray Patches (VMAPs) Revenue Growth Rate (US$ Million), 2021–2032

Figure 61. Saudi Arabia Vaccine Microarray Patches (VMAPs) Revenue Growth Rate (US$ Million), 2021–2032

Figure 62. UAE Vaccine Microarray Patches (VMAPs) Revenue Growth Rate (US$ Million), 2021–2032

Figure 63. Global Sales Market Share of Vaccine Microarray Patches (VMAPs) by Type (2021–2032)

Figure 64. Global Revenue Market Share of Vaccine Microarray Patches (VMAPs) by Type (2021–2032)

Figure 65. Global Vaccine Microarray Patches (VMAPs) Price (US$/Pc) by Type (2021–2032)

Figure 66. Global Sales Market Share of Vaccine Microarray Patches (VMAPs) by Application (2021–2032)

Figure 67. Global Revenue Market Share of Vaccine Microarray Patches (VMAPs) by Application (2021–2032)

Figure 68. Global Vaccine Microarray Patches (VMAPs) Price (US$/Pc) by Application (2021–2032)

Figure 69. Vaccine Microarray Patches (VMAPs) Value Chain

Figure 70. Channels of Distribution (Direct Vs Distribution)

Figure 71. Bottom-up and Top-down Approaches for This Report

Figure 72. Data Triangulation

Figure 73. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic

$2900

Single User License

Multi User

Electronic

$4350

Multi User License

Enterprise License

Electronic

$5800

Enterprise License

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions